Back to Authors

Wang, M. L.

Mayo Clinic

The University of Texas MD Anderson Cancer Center

Citations 3

PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS, SUBGROUP ANALYSIS FROM BRUIN WITH >3 YEARS FOLLOW‐UP FROM START OF ENROLLMENT
Shah, Nirav N. , Eyre, Toby A. , Ujjani, Chaitra S. , Alencar, Alvaro J. , Lewis, David , Maddocks, Kami J. , Wang, Y., Munir, T, Balbas, Minna, Tsai, Donald E. , Wang, C., Wang, M. L., Cheah, Chan Y. , Jurczak, Wojciech , Zinzani, Pier Luigi , Izutsu, Koji , Ma, Shuo , Flinn, Ian W. , Patel, Krish , Wang, Yucai , Zelenetz, Andrew D.

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 153-156

10.1002/hon.3163_102 Get It

P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS)
Eyre, Toby A. , Shah, N. N., Dreyling, Martin, Wang, Y., Gandhi, M., Chay, C., Sharman, Jeff P. , Andorsky, David , Yin, Ming , Balbas, Minna, Kherani, Jennifer , Wang, M. L., Gouill, Steven Le , Vandenberghe, Elisabeth , Jurczak, Wojciech , Wang, Yucai , Cheah, Chan Y. , Yin, M.

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 990-991

10.1097/01.hs9.0000847268.67095.fc Get It